← 返回

糖酵解和 T 细胞相关基因特征预测胰腺癌的预后和治疗反应

英文原题:Glycolysis and T cell-associated gene signature predicts prognosis and therapeutic responses in pancreatic cancer.

查看英文原题

Glycolysis and T cell-associated gene signature predicts prognosis and therapeutic responses in pancreatic cancer.

PubMed 2026/08/28(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

MET、KDELR3、AK4 和 GPR87 被确定为 PC 的候选预后基因,提供了初步的产生假设的见解,在应用于临床之前需要在独立机构或前瞻性临床队列中进行验证。

研究思路结论见上方概要

胰腺癌(PC)是一种致命的恶性肿瘤,糖酵解和T细胞在其发病机制中起着至关重要的作用。本研究利用生物信息学方法探讨了PC中糖酵解和T细胞相关的预后基因。

我们首先通过对TCGA-PAAD队列的免疫浸润分析量化了不同的T细胞亚群,并提取了T细胞相关基因(T-RGs)。从GSE28735和TCGA-PAAD中获取差异表达基因(DEGs)。将这些DEGs与T-RGs和糖酵解相关基因(G-RGs)取交集,得到候选基因。我们使用单因素Cox和LASSO回归筛选预后基因,在TCGA-PAAD中构建预后模型,并在GSE57495中进行验证。构建列线图用于生存预测,通过校准曲线和ROC曲线验证其可靠性。我们比较了高、低风险亚组之间的免疫微环境、通路富集、突变景观和药物敏感性,并构建了lncRNA-miRNA-mRNA调控网络。通过体外和体内小鼠致瘤实验探索了GPR87在糖酵解活性和CD8+ T细胞浸润中的潜在参与。Seahorse分析、葡萄糖摄取检测和免疫组化进一步探索了其在葡萄糖代谢和抗肿瘤免疫中的作用。

MET、KDELR3、AK4 和 GPR87 被确定为预后基因。在训练集中,该探索性预后模型显示出中等预测性能,1 年、2 年和 3 年的曲线下面积值分别为 0.72、0.71 和 0.71。风险评分和 N 分期被确定为独立预后预测因素,所开发的列线图显示出中等预测性能。功能通路显示富集于 44 条通路。有 17 种差异免疫细胞。此外,风险评分与 28 个免疫检查点相关。调控网络由 26 个 miRNAs 和 50 个 lncRNAs 组成。此外,在不同风险组中鉴定出计算预测的预后基因与 60 种药物之间的相关性。体外和体内实验表明,GPR87 敲低抑制 PC 细胞的增殖、迁移和克隆形成能力,同时促进其凋亡。此外,GPR87 表达与 CD8 + T 细胞呈负相关,且 GPR87 敲低抑制胰腺癌细胞中的糖酵解。

展开英文摘要原文

Pancreatic cancer (PC) is a fatal malignancy, with glycolysis and T cells playing crucial roles in its pathogenesis. This study explored prognosis-related genes in glycolysis and T cells in PC using bioinformatics methods.

We first quantified distinct T-cell subsets via immune infiltration analysis of the TCGA-PAAD cohort and extracted T cell-related genes (T-RGs). Differentially expressed genes (DEGs) were obtained from GSE28735 and TCGA-PAAD. Intersecting these DEGs with T-RGs and glycolysis-related genes (G-RGs) yielded candidate genes. We screened prognostic genes using univariate Cox and LASSO regression, built a prognostic model in TCGA-PAAD and validated it in GSE57495. A nomogram was constructed for survival prediction, its reliability verified by calibration and ROC curves. We compared immune microenvironment, pathway enrichment, mutation landscape and drug sensitivity between high- and low-risk subgroups, and built lncRNA-miRNA-mRNA regulatory networks. In vitro and in vivo mouse tumorigenesis assays explored GPR87's potential involvement in glycolytic activity and CD8 + T cell infiltration. Seahorse analysis, glucose uptake detection and immunohistochemistry further explored roles in glucose metabolism and anti-tumor immunity.

MET , KDELR3 , AK4 , and GPR87 were determined as prognostic genes. In the training set, this exploratory prognostic model showed moderate predictive performance, with area under the curve values of 0.72, 0.71, and 0.71 at 1, 2, and 3 years, respectively. The risk score and N-stage were identified as independent prognosis predictors, and the developed nomogram demonstrated moderate predictive performance. Functional pathways revealed enrichment in 44 pathways. There were 17 differential immune cells. In addition, risk scores were correlated with 28 immune checkpoints. The regulatory network comprised 26 miRNAs and 50 lncRNAs. Furthermore, computationally predicted correlations between prognostic genes and 60 drugs were identified in different risk groups. In vitro and in vivo experiments demonstrated that GPR87 knockdown inhibits the proliferation, migration, and clonogenic ability of PC cells while promoting their apoptosis. Furthermore, GPR87 expression was negatively correlated with CD8 + T cell, and GPR87 knockdown inhibited glycolysis in pancreatic cancer cells.

MET , KDELR3 , AK4 , and GPR87 were identified as candidate prognostic genes in PC, providing preliminary hypothesis-generating insights that require validation in independent institutional or prospective clinical cohorts before any clinical application.

论文信息

作者
Li W、Fan D、Du Y、Li L、Li W、Zhou W
单位
The Second School of Clinical Medicine, Lanzhou University, Lanzhou, China.China
期刊
Frontiers in immunology2026
原文标识
PubMed 42729487 · DOI 10.3389/fimmu.2026.1918556